A recent study of HIV-infected patients coinfected with hepatitis B and C viruses found that, despite increasing use of antiretrovirals, no clear reduction in end-stage liver disease risk was observed. The authors said treatment with direct acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.
HIV incidence, prevalence, and undiagnosed infections can be estimated using HIV case surveillance data and information on first CD4 test result after diagnosis, according to analysis published in JAIDS.
On Twitter @richpizzi